About

Apexigen is a clinical-stage biopharmaceutical company discovering and developing the next generation of antibody therapeutics for the treatment of cancer with an emphasis on new immuno-oncology products that harness the patient’s immune system to combat and eradicate cancer.

Immuno-oncology

Recent advances in cancer immunology have increased our understanding of the mechanisms that cancer cells use to either avoid detection by or to de-activate the immune system. Novel immuno-oncology drugs are designed specifically to block immune suppression induced by tumors, or to actively initiate and augment an immune response against tumors. Manipulating the body’s immune system can lead to elimination of tumors and prevention of tumor recurrence (for a long-lasting cure).

Apexigen’s Immuno-oncology Strategy

Apexigen is focused on discovering and developing innovative drugs that enhance tumor-specific immunity. The use of its APXiMAB™ platform  enables Apexigen to discover antibodies with unique attributes against known and novel immune system targets. These antibodies have demonstrated the potential to become the next generation of cancer therapies as we progress toward the ultimate cure for cancer.

News

March 6, 2018
Apexigen and the Pediatric Brain Tumor Consortium Announce a Clinical Collaboration to Evaluate APX005M in Children with Brain Tumors
Study to evaluate the safety and tolerability of APX005M, a CD40 agonistic antibody, in pediatric patients with recurrent or refractory brain tumors

October 31, 2017
Apexigen Announces Late-Breaking Oral Presentation for Immune Activating Antibody APX005M at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 25, 2017
Apexigen Announces New Collaboration with UCSF
Clinical Trial Collaboration to Evaluate Apexigen’s Immune Activating Antibody APX005M in Combination with Multimodality Treatment of Resectable Esophageal and Gastro-Esophageal Junction Cancers

September 20, 2017
The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute Announce First Patients Treated in Pancreatic Cancer Clinical Trial Combining Immunotherapy and Chemotherapy
Collaboration with Bristol-Myers Squibb, Apexigen will test CD40 antibody APX005M, nivolumab and chemotherapy

Read more news.